Skip to main content

Table 2 Characteristics compared between those with and without metabolic syndrome further compared among all included patients, ankylosing spondylitis patients, and psoriatic arthritis patients

From: Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study

Characteristics All
(n = 319)
Ankylosing spondylitis
(n = 153)
Psoriatic arthritis
(n = 166)
Metabolic syndrome Metabolic syndrome Metabolic syndrome
Yes
(n = 101)
No
(n = 218)
Yes
(n = 29)
No
(n = 124)
Yes
(n = 72)
No
(n = 94)
Number of MetS criteria, median (IQR) 4.0 (1.0) 1.0 (2.0)* 4.0 (1.0) 1.0 (2.0)* 3.5 (1.0) 1.0(2.0)*
Elevated WC, n (%) 93 (92.1%) 60 (27.5%)* 24 (82.8%) 34 (27.4%)* 69 (95.8%) 26 (27.7%)*
Elevated BP, n (%) 87 (86.1%) 55 (25.2%)* 24 (82.8%) 28 (22.6%)* 63 (87.5%) 27 (28.7%)*
Elevated FG, n (%) 74 (73.3%) 38 (17.4%)* 23 (79.3%) 13 (10.5%)* 51 (70.8%) 25 (26.6%)*
Elevated TG, n (%) 50 (49.5%) 20 (9.2%)* 12 (41.4%) 12 (9.7%)* 38 (52.8%) 8 (8.5%)*
Reduced HDL-C, n (%) 63 (62.4%) 26 (11.9%)* 21 (72.4%) 12(9.7%)* 42 (58.3%) 14 (14.9%)*
Age (yrs), mean ± SD 52.3 ± 10.1 42.3 ± 11.9* 48.0 ± 9.2 40.3 ± 11.2* 54.0 ± 9.9 45.1 ± 12.3*
Female gender, n (%) 55 (54.5%) 93 (42.7%)* 8 (27.6%) 51 (41.1%) 47 (65.3%) 42 (44.7%)*
History of smoking, n (%) 13 (12.9%) 42 (19.3%) 4 (13.8%) 18 (14.5%) 9 (12.5%) 24 (25.5%)*
Current smoker, n (%) 5 (5.0%) 22 (10.1%) 3 (10.3%) 9 (7.3%) 2 (2.8%) 13 (13.8%)*
Current exercise, n (%) 40 (39.6%) 94 (43.1%) 9 (31.0%) 40 (49.2%) 31 (43.1%) 33 (35.1%)
Physical work, n (%) 37 (36.6%) 85 (39.0%) 8 (27.6%) 41 (33.1%) 29 (40.3%) 44 (46.8%)
BMI (kg/m2), mean ± SD 27.2 ± 6.0 23.1 ± 4.5* 27.0 ± 4.5 22.5 ± 4.6* 27.3 ± 4.5 23.7 ± 4.3*
Disease duration (yrs), median (IQR) 5.0 (8.0) 5.0 (9.0) 10.0(14.5) 10(13.8) 3.0(6.5) 3.0(4.6)
ASDAS-CRP, mean (SD) 2.0 (1.1) 2.2 (1.1) 2.0 (1.1) 2.2(1.1) 2.0 (1.1) 2.3 (1.2)
DAPSA, median (IQR) N/A N/A N/A N/A 6.3 (10.5) 9.1 (12)
cDAPSA, median (IQR) N/A N/A N/A N/A 6.0(9.5) 8.0 (11)
No. of SynAnk, median (IQR) 5.5 (8.0) 2.0 (7.0)* 5.0 (11.5) 2.0 (10.0)* 6.0 (9.0) 2.0 (5.0)*
Current DMARDs, median (IQR) 1.0 (1.5) 1.0 (0) 1.0 (1.5) 1.0 (1.0) 1.0 (1.0) 1.0 (0.25)
Current NSAIDs, n (%) 34 (33.7%) 81 (37.2%) 12 (41.3%) 53 (42.7%) 22 (30.6%) 28 (29.8%)
  1. *Indicates a p-value< 0.05
  2. Abbreviations: MetS Metabolic syndrome; IQR Interquartile range; WC Waist circumference; BP Blood pressure; FG Fasting glucose; TG Triglycerides; HDL-C High-density lipoprotein cholesterol; SD Standard deviation; BMI Body mass index; ASDAS-CRP Ankylosing Spondylitis Disease Activity - C-reactive protein; cDAPSA Clinical Disease Activity Index for Psoriatic Arthritis; DAPSA Disease Activity Index for Psoriatic Arthritis; SynAnk Syndesmophyte or ankylosis; DMARDs Disease modifying antirheumatic drugs; NSAIDs Non-steroidal anti-inflammatory drugs, N/A Not applicable